Participate in Research at CU Anschutz

To determine the tolerability of empagliflozin as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Participation involves taking the study drug empagliflozin or a placebo for 12 months. Blood sample collection, magnetic resonance imaging (MRI) of the kidneys and blood vessel stiffness testing during visits at baseline, 3-month and 12-month to the Renal Research Clinic located at the University of Colorado Anschutz Medical Campus or the University and regular telephone or telemedicine visits. If traveling to the University of Colorado from out-of-state, your airfare and hotel will be arranged and paid for by the study.